IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity

IRF4 缺陷通过体细胞获得的 Jak3 突变赋予 IL-7 超敏反应,使 B 细胞后代易患白血病。

阅读:4
作者:Dennis Das Gupta ,Christoph Paul ,Nadine Samel ,Maria Bieringer ,Daniel Staudenraus ,Federico Marini ,Hartmann Raifer ,Lisa Menke ,Lea Hansal ,Bärbel Camara ,Edith Roth ,Patrick Daum ,Michael Wanzel ,Marco Mernberger ,Andrea Nist ,Uta-Maria Bauer ,Frederik Helmprobst ,Malte Buchholz ,Katrin Roth ,Lorenz Bastian ,Alina M Hartmann ,Claudia Baldus ,Koichi Ikuta ,Andreas Neubauer ,Andreas Burchert ,Hans-Martin Jäck ,Matthias Klein ,Tobias Bopp ,Thorsten Stiewe ,Axel Pagenstecher ,Michael Lohoff

Abstract

The processes leading from disturbed B-cell development to adult B-cell progenitor acute lymphoblastic leukemia (BCP-ALL) remain poorly understood. Here, we describe Irf4-/- mice as prone to developing BCP-ALL with age. Irf4-/- preB-I cells exhibited impaired differentiation but enhanced proliferation in response to IL-7, along with reduced retention in the IL-7 providing bone marrow niche due to decreased CXCL12 responsiveness. Thus selected, preB-I cells acquired Jak3 mutations, probably following irregular AID activity, resulting in malignant transformation. We demonstrate heightened IL-7 sensitivity due to Jak3 mutants, devise a model to explain it, and describe structural and functional similarities to Jak2 mutations often occurring in human Ph-like ALL. Finally, targeting JAK signaling with Ruxolitinib in vivo prolonged survival of mice bearing established Irf4-/- leukemia. Intriguingly, organ infiltration including leukemic meningeosis was selectively reduced without affecting blood blast counts. In this work, we present spontaneous leukemogenesis following IRF4 deficiency with potential implications for high-risk BCP-ALL in adult humans.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。